

2015
Press release



www.genfit.com

GENFIT: MINUTES OF THE COMBINED GENERAL SHAREHOLDERS' MEETING OF FEBRUARY 24, 2015

- **A large majority of shareholders adopted the totality of the resolutions proposed by the Management Board**

Lille (France), Boston (Massachusetts, United States), February 24th, 2015 – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that its share holders have voted in favor of the totality of the resolutions proposed by the Management Board during the Combined Shareholders' Meeting that was held in Lille on February 24, 2015.

The shareholders approved all the resolutions proposed by the Management Board by a large majority of at least 87% of the cast votes.

Jean-François Mouney, Chairman and CEO of GENFIT, declared: *"We note with satisfaction the high level of participation of our shareholders, since a quorum of more than 30% of the shares that form the Company's share capital was reached, despite the technical nature of the Agenda. We would like to thank both our institutional and individual shareholders who, by voting the totality of the resolutions proposed with a comfortable majority, show their support for the Management Board."*

The presentation that accompanied the meeting is available in the Documentation Center of the Company's web-site (www.genfit.com). The detail of the voting results for each resolution will be available shortly.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH.

With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on GENFIT's website (www.genfit.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.

Contacts

GENFIT | Jean-François Mouney - CEO & Chairman of the Management Board | Ph. +333 2016 4000

MILESTONES – Relation Presse | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – barabian@milestones.fr